



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/724,254	11/28/2000	Riccardo Dalla-Favera	58044-A/JPW/EMW	5325

7590 03/26/2002

John P White Esquire
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036

EXAMINER

CANELLA, KAREN A

ART UNIT	PAPER NUMBER
----------	--------------

1642

7

DATE MAILED: 03/26/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

09/724,254

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.


EXAMINER	
ART UNIT	PAPER NUMBER
	7

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application
Commissioner of Patents

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.R.F. § 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the content of the Sequence Listing, filed January 14, 2002 does not correspond to the content of Figure 18. For instance, claims 2 and 3 are drawn to the IRTA1 and IRTA2 proteins as set forth in figure 18A (SEQ ID NO:1) and 18B (SEQ ID NO:3), respectively. However, both SEQ ID NO:1 and SEQ ID NO:2 are polynucleotides consisting of 90 nucleotides. In addition Claims 4, 5 and 6 are drawn to the IRTA3, 4 and 5 proteins as set forth in figures 18C (SEQ ID NO:5), 18D (SEQ ID NO:7) and 18E (SEQ ID NO:9) as 734, 524 and 339 amino acid residues, respectively. However, the Sequence Listing indicates that SEQ ID NO:5, 7 and 9 are 518, 728 and 591 amino acid residues, respectively. Appropriate correction of the Sequence Listing, the CRF or the specification, is required.
2. Any questions regarding compliance with the sequence rules requirements specifically should be directed to Mark Spencer at 703-308-4212.
3. Applicant is given a TIME PERIOD of **ONE (1) MONTH** or **THIRTY (30) DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Karen A. Canella, Ph.D
Patent Examiner, Group 1642
(703) 308-8362


ANTHONY C. CAPUTA
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600